Download PDF
Thromb Haemost 1998; 80(01): 176-180
DOI: 10.1055/s-0037-1615159
Rapid Communication
Schattauer GmbH

Chrono-lume® and Magnesium Potentiate Aggregation of Canine but not Human Platelets in Citrated Platelet-Rich Plasma

Mary Beth Callan
1   Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
,
Frances S. Shofer
1   Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
,
Carol Wojenski
2   Cardeza Foundation and Department of Biochemistry and Molecular Pharmacology, Thomas Jefferson Medical College, Philadelphia, PA, USA
,
Urs Giger
1   Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA
› Author AffiliationsSupported in part by grants HL-02355 and RR-02512 from the National Institutes of Health and by Chrono-log Corporation, Havertown, PA.
Further Information

Publication History

Received 03 November 1997

Accepted after resubmission 30 March 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

The effects of Chrono-lume® (CL) and magnesium sulfate (Mg2+), a component of this luciferin-luciferase reagent, on platelet aggregation were studied in platelet-rich plasma (PRP) obtained from blood anticoagulated with sodium citrate from humans, dogs, cats, horses, and cows. The final added Mg2+ concentration of both solutions ranged from 0.75-3.7 mM. CL and Mg2+ had no effect on maximum aggregation of platelets from humans induced by sub-threshold concentrations of collagen and ADP. In contrast, addition of CL or Mg2+ to canine PRP resulted in a dose-dependent and equal potentiation of platelet aggregation in response to sub-threshold concentrations of collagen, ADP, and thrombin in normal and thrombopathic dogs. The effect of CL on platelet aggregation induced by sub-threshold concentrations of agonists was less pronounced and varied in other species according to the agonist. The reason for the marked difference in sensitivity of human and canine platelets to CL or Mg2+ is not clear, although a difference in releasable cation pools of the platelets from these two species has been recognized. Platelet aggregation studies of animals with suspected thrombopathias should be performed without CL to prevent masking of a platelet function defect.

 

  • References

  • 1 Feinman RD, Lubowsky J, Charo I, Zabinski MP. The lumi-aggregometer: a new instrument for simultaneous measurement of secretion and aggregation by platelets. J Lab Clin Med 1977; 90: 125-9.
    PubMedGoogle Scholar
  • 2 Mehta P, Mehta J, Ostrowski N, Aguila E. Potentiation of platelet aggregation by Chrono-lume. Thromb Res 1983; 32: 509-12.
    CrossrefPubMedGoogle Scholar
  • 3 Pfueller SL, Broadway M. Inhibition of platelet aggregation and [14C] serotonin release by luciferin:luciferase preparations. Thromb Res 1986; 44: 539-42.
    CrossrefPubMedGoogle Scholar
  • 4 Thompson NT, Scrutton MC. Inhibition by luciferin-luciferase reagents of aggregatory response to excitatory agonists in washed platelet suspensions. Thromb Res 1985; 38: 109-19.
    CrossrefPubMedGoogle Scholar
  • 5 LeRoy EC, Mason RG, Brinkhous KM. Species differences in platelet agglutination in man and in the dog, swine, and rabbit. Am J Physiol 1960; 199: 183-6.
    PubMedGoogle Scholar
  • 6 Catalfamo JL, Dodds WJ. Isolation of platelets from laboratory animals. In: Methods in Enzymology, Vol. 169. Hawiger J. ed. Academic Press; San Diego: 1989. pp. 27-34.
    Google Scholar
  • 7 Feinman RD, Detwiler TC, Ingerman-Wojenski C. The lumi-aggregometer as a research and clinical tool. In: The Platelets: Physiology and Pharmacology. Longenecker G. L.. ed. Academic Press; Orlando: 1985. pp. 429-40.
    Google Scholar
  • 8 Huang EM, McGowan EB, Detwiler TC. Succinate potentiates the action of platelet agonists. Thromb Res 1984; 36: 1-8.
    CrossrefPubMedGoogle Scholar
  • 9 Brinkhous KM, LeRoy EC, Cornell WP, Brown RC, Hazlehurst JL, Vennart GP. Macroscopic studies of platelet agglutination; nature of thrombocyte agglutinating activity of plasma. Proc Soc Exp Biol Med 1958; 98: 379-83.
    CrossrefPubMedGoogle Scholar
  • 10 Mason RG, LeRoy EC, Brinkhous KM. Cation specificity of thrombocyte agglutinating activity (TAg) of canine plasma. Proc Soc Exp Biol Med 1959; 102: 253-5.
    CrossrefPubMedGoogle Scholar
  • 11 Hwang DL, Yen CF, Nadler JL. Effect of extracellular magnesium on platelet activation and intracellular calcium mobilization. Am J Hypertens 1992; 5: 700-6.
    CrossrefPubMedGoogle Scholar
  • 12 Ravn HB, Vissinger H, Kristensen SD, Husted SE. Magnesium inhibits platelet activity - an in vitro study. Thromb Haemost 1996; 76: 88-93.
    PubMedGoogle Scholar
  • 13 Gawaz M, Ott I, Reininger AJ, Neumann FJ. Effects of magnesium on platelet aggregation and adhesion. Thromb Haemost 1994; 72: 912-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Nadler J, Malayan S, Luong H. Evidence that intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus. Diabetes Care 1992; 15: 835-41.
    CrossrefPubMedGoogle Scholar
  • 15 Resnick LM, Gupta RK, Bhargava KK. et al. Cellular ions in hypertension, diabetes, and obesity. Hypertension 1991; 17: 951-7.
    CrossrefPubMedGoogle Scholar
  • 16 Meyers KM, Holmsen H, Seachord CL. Comparative study of platelet dense granule constituents. Am J Physiol 1982; 243: R454-61.
    PubMedGoogle Scholar
  • 17 Soslau G, Parker J. The bioluminescent detection of platelet released ATP: collagen-induced release and potential errors. Thromb Res 1992; 66: 15-21.
    CrossrefPubMedGoogle Scholar